Outlook Therapeutics provides update on progress towards first approved ophthalmic formulation of bevacizumab-vikg (Lytenava) for advanced macular degeneration

Company has completed enrolment of 227 patients in U.S.-based phase 3 pivotal trial, with data expected mid-2021 followed by submission of a Biologics Licence Application to FDA and Marketing Authorization Application to EMA in 2021, with planned commercial launch in 2022.

Source:

Biospace Inc.